FISH for AML/ETO - t(8;21)

The test is performed on a sample of blood or bone marrow. Fluorescent probes specific to the regions of interest on chromosomes 8 and 21 are used. These probes bind to the chromosomes, and under a fluorescence microscope, the lab technician can observe whether or not the AML/ETO fusion gene is present.

If the test detects the AML/ETO fusion gene, it suggests the presence of the t(8;21) translocation and confirms the diagnosis of a specific subtype of AML. If not detected, the patient likely does not have this subtype of AML.

Knowing the presence of the AML/ETO fusion gene helps doctors determine the appropriate treatment protocol for the patient. Patients with this fusion gene might require a different treatment approach compared to those without it.

The test is generally recommended for individuals suspected to have AML, particularly if they exhibit specific symptoms or have abnormal results from other blood tests.

The risks are primarily associated with the collection of blood or bone marrow samples, including pain, infection, or bruising at the puncture site.

Technical issues or the quality of the sample might affect the test results. It is essential that the test be conducted by an accredited laboratory to minimize any errors.

The AML/ETO fusion gene is believed to play a role in blocking the normal differentiation of blood cells, leading to an accumulation of immature blood cells, which is characteristic of AML.

Yes, the FISH for AML/ETO - t(8;21) test can be used to monitor minimal residual disease and to evaluate the effectiveness of treatment.

Yes, patients with the AML/ETO fusion gene often have a more favorable prognosis compared to other subtypes of AML. However, the overall outcome also depends on various other factors including patient's age, general health, and response to treatment.

As with any diagnostic test, there is a possibility of false-positive or false-negative results. This is why it's important that the test be interpreted in conjunction with other diagnostic information.

This test is not used for screening family members as AML with the t(8;21) translocation is not inherited.

If the test results are positive, it is crucial to consult with your doctor to understand the results and discuss the next steps in managing your condition.

Yes, alternative tests include reverse transcription-polymerase chain reaction (RT-PCR) and conventional cytogenetics. Your doctor can advise on which test is most suitable for your condition.

The FISH for AML/ETO - t(8;21) is a vital diagnostic tool that can provide essential information for diagnosing, managing, and monitoring a specific subtype of acute myeloid leukemia. The test's results can help in making important treatment decisions. If you have been diagnosed with AML or are experiencing symptoms consistent with leukemia, consult your doctor to discuss if the FISH for AML/ETO - t(8;21) test is appropriate for you.